The natural history of MPS I: global perspectives from the MPS I Registry
Open Access
- 1 October 2014
- journal article
- research article
- Published by Elsevier BV in Genetics in Medicine
- Vol. 16 (10), 759-765
- https://doi.org/10.1038/gim.2014.25
Abstract
No abstract availableFunding Information
- BioMarin Pharmaceutical
- Shire
- Genzyme
- Actelion Pharmaceuticals
This publication has 18 references indexed in Scilit:
- Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I RegistryEuropean Journal of Pediatrics, 2012
- Childhood onset of Scheie syndrome, the attenuated form of mucopolysaccharidosis IJournal of Inherited Metabolic Disease, 2010
- Mucopolysaccharidosis I: Management and Treatment GuidelinesPEDIATRICS, 2009
- Long-term Efficacy and Safety of Laronidase in the Treatment of Mucopolysaccharidosis IPEDIATRICS, 2009
- Enzyme Replacement Therapy in Patients Who Have Mucopolysaccharidosis I and Are Younger Than 5 Years: Results of a Multinational Study of Recombinant Human α-l-Iduronidase (Laronidase)PEDIATRICS, 2007
- The MPS I registry: Design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type IMolecular Genetics and Metabolism, 2007
- A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 yearsMolecular Genetics and Metabolism, 2007
- Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (laronidase)The Journal of Pediatrics, 2004
- DiscussionThe American Journal of Cardiology, 1999
- Problems in the Use of Large Data Sets to Assess EffectivenessInternational Journal of Technology Assessment in Health Care, 1990